It's official: dramatic share price jumps in response to clinical data have become more common.
A focus on rare diseases and regulatory acceptance of cannabis make GW the subject of a $7.2bn buyout.
Pharmamar’s pivotal small cell lung cancer trial is finally confirmed a dud, but will the FDA pull Zepzelca from the market?
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.